Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
The main purpose of this clinical trial is to examine the feasibility and effects of
tamoxifen in subjects with pulmonary arterial hypertension (PAH). The study will evaluate how
well the drug is tolerated, and its impact on functional condition and selected biomarkers.
Changes in tricuspid annular plane systolic excursion (TAPSE) and other parameters determined
by transthoracic echocardiography will be evaluated as well as changes in additional metrics
such as six minute walk test distance, quality of life assessments, and hormone levels.